Test dell'aggiunta di MEDI4736 (Durvalumab) alla chemioterapia prima dell'intervento chirurgico per i pazienti con carcinoma del tratto urinario superiore di alto grado
Uno studio di fase II/III su MEDI4736 (Durvalumab) e chemioterapia per pazienti con carcinoma uroteliale del tratto superiore di alto grado prima della nefroureterectomia
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Droga: Cisplatin
- Procedura: Biospecimen Collection
- Droga: Methotrexate
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Droga: Gemcitabine Hydrochloride
- Procedura: Therapeutic Conventional Surgery
- Procedura: Biopsy Procedure
- Biologico: Durvalumab
- Droga: Doxorubicin Hydrochloride
- Biologico: Pegfilgrastim
- Droga: Vinblastine Sulfate
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To compare event-free survival (EFS) between patients with upper tract urothelial cancer (UTUC) randomized to neoadjuvant accelerated methotrexate, vinblastine, Adriamycin, cisplatin (aMVAC) alone or in combination with durvalumab. (Cisplatin eligible patients [Arms A and B]) II. Evaluation of pathologic complete response at radical nephroureterectomy (RNU) (pathologic complete response [pCR], ypT0N0/Nx). (Cisplatin ineligible patients [Arm C]).
SECONDARY OBJECTIVES:
I. To assess pathologic complete response (pCR) at surgery. (Cisplatin eligible cohort) II. Event-free survival (EFS) will be evaluated for the cisplatin ineligible cohort as a secondary endpoint. (Cisplatin ineligible cohort) III. Overall survival in all, and by post chemotherapy response (ypT0N0, yp =< T1N0, yp >= T2Nany). (All patients) IV. To evaluate disease-free survival (DFS) in each arm of the trial separately. (All patients) V. To evaluate cancer-specific survival of patients in each arm of the trial separately. (All patients) VI. To evaluate renal function outcomes following systemic treatment and following surgery ([RNU) in each arm of the trial separately. (All patients) VII. To evaluate safety and tolerability of neoadjuvant aMVAC alone or in combination with durvalumab prior to RNU. (All patients)
OUTLINE: Patients eligible for cisplatin are randomized to Arms A or B. Patients ineligible for cisplatin are assigned to Arm C.
ARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM B: Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM C: Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
Patients also undergo tissue biopsy and blood sample collection on study, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.
After completion of study treatment, patients are followed up within 30 days and then every 3-6 months for up to 5 years from study entry.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Kingman, Arizona, Stati Uniti, 86401
- Reclutamento
- Kingman Regional Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 702-384-0013
- Email: research@sncrf.org
-
Investigatore principale:
- Khawaja S. Jahangir
-
-
Arkansas
-
Fort Smith, Arkansas, Stati Uniti, 72903
- Sospeso
- Mercy Hospital Fort Smith
-
Little Rock, Arkansas, Stati Uniti, 72205
- Attivo, non reclutante
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, Stati Uniti, 95602
- Attivo, non reclutante
- Sutter Auburn Faith Hospital
-
Berkeley, California, Stati Uniti, 94704
- Attivo, non reclutante
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Stati Uniti, 91010
- Attivo, non reclutante
- City of Hope Comprehensive Cancer Center
-
Fremont, California, Stati Uniti, 94538
- Attivo, non reclutante
- Palo Alto Medical Foundation-Fremont
-
La Jolla, California, Stati Uniti, 92093
- Reclutamento
- UC San Diego Moores Cancer Center
-
Investigatore principale:
- Aditya Bagrodia
-
Contatto:
- Site Public Contact
- Numero di telefono: 858-822-5354
- Email: cancercto@ucsd.edu
-
Modesto, California, Stati Uniti, 95355
- Attivo, non reclutante
- Memorial Medical Center
-
Mountain View, California, Stati Uniti, 94040
- Attivo, non reclutante
- Palo Alto Medical Foundation-Camino Division
-
Palo Alto, California, Stati Uniti, 94304
- Reclutamento
- Stanford Cancer Institute Palo Alto
-
Investigatore principale:
- Ali R. Khaki
-
Contatto:
- Site Public Contact
- Numero di telefono: 650-498-7061
- Email: cancertrialsinfo@stanford.edu
-
Palo Alto, California, Stati Uniti, 94301
- Attivo, non reclutante
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Stati Uniti, 95661
- Attivo, non reclutante
- Sutter Roseville Medical Center
-
Sacramento, California, Stati Uniti, 95816
- Attivo, non reclutante
- Sutter Medical Center Sacramento
-
San Diego, California, Stati Uniti, 92103
- Reclutamento
- UC San Diego Medical Center - Hillcrest
-
Investigatore principale:
- Aditya Bagrodia
-
Contatto:
- Site Public Contact
- Email: rhabbaba@health.ucsd.edu
-
San Francisco, California, Stati Uniti, 94115
- Attivo, non reclutante
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz, California, Stati Uniti, 95065
- Attivo, non reclutante
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Stati Uniti, 95403
- Attivo, non reclutante
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Stati Uniti, 94086
- Attivo, non reclutante
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Stati Uniti, 94589
- Attivo, non reclutante
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- UCHealth University of Colorado Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 720-848-0650
-
Investigatore principale:
- Elizabeth R. Kessler
-
Denver, Colorado, Stati Uniti, 80206
- Sospeso
- UCHealth - Cherry Creek
-
Fort Collins, Colorado, Stati Uniti, 80524
- Reclutamento
- Poudre Valley Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 970-297-6150
-
Investigatore principale:
- Elizabeth R. Kessler
-
Fort Collins, Colorado, Stati Uniti, 80528
- Reclutamento
- Cancer Care and Hematology-Fort Collins
-
Contatto:
- Site Public Contact
- Email: ecog.rss@jimmy.harvard.edu
-
Investigatore principale:
- Elizabeth R. Kessler
-
Greeley, Colorado, Stati Uniti, 80631
- Reclutamento
- UCHealth Greeley Hospital
-
Contatto:
- Site Public Contact
- Email: ecog.rss@jimmy.harvard.edu
-
Investigatore principale:
- Elizabeth R. Kessler
-
Highlands Ranch, Colorado, Stati Uniti, 80129
- Reclutamento
- UCHealth Highlands Ranch Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 720-848-0650
-
Investigatore principale:
- Elizabeth R. Kessler
-
Lone Tree, Colorado, Stati Uniti, 80124
- Reclutamento
- UCHealth Lone Tree Health Center
-
Contatto:
- Site Public Contact
- Email: ecog.rss@jimmy.harvard.edu
-
Investigatore principale:
- Elizabeth R. Kessler
-
Loveland, Colorado, Stati Uniti, 80538
- Reclutamento
- Medical Center of the Rockies
-
Contatto:
- Site Public Contact
- Numero di telefono: 970-203-7083
-
Investigatore principale:
- Elizabeth R. Kessler
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20016
- Reclutamento
- Sibley Memorial Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 202-243-2373
- Email: jquiver1@jhmi.edu
-
Investigatore principale:
- Jean H. Hoffman-Censits
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Reclutamento
- MedStar Washington Hospital Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 202-877-8839
-
Investigatore principale:
- Suthee Rapisuwon
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224-9980
- Attivo, non reclutante
- Mayo Clinic in Florida
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University Hospital/Winship Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-778-1868
-
Investigatore principale:
- Jacqueline T. Brown
-
Atlanta, Georgia, Stati Uniti, 30308
- Reclutamento
- Emory University Hospital Midtown
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-946-7447
-
Investigatore principale:
- Jacqueline T. Brown
-
Atlanta, Georgia, Stati Uniti, 30342
- Reclutamento
- Emory Saint Joseph's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-851-7115
-
Investigatore principale:
- Jacqueline T. Brown
-
Decatur, Georgia, Stati Uniti, 30033
- Reclutamento
- Emory Decatur Hospital
-
Investigatore principale:
- Jacqueline T. Brown
-
Contatto:
- Site Public Contact
- Numero di telefono: 440-778-1868
- Email: clinicaltrialsoncology@dekalbmedical.org
-
-
Idaho
-
Nampa, Idaho, Stati Uniti, 83687
- Reclutamento
- Saint Alphonsus Cancer Care Center-Nampa
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Investigatore principale:
- Elie G. Dib
-
-
Illinois
-
Alton, Illinois, Stati Uniti, 62002
- Sospeso
- OSF Saint Anthony's Health Center
-
Barrington, Illinois, Stati Uniti, 60010
- Reclutamento
- Advocate Good Shepherd Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-842-4847
-
Investigatore principale:
- Thomas J. Saphner
-
Bloomington, Illinois, Stati Uniti, 61704
- Attivo, non reclutante
- Illinois CancerCare-Bloomington
-
Burr Ridge, Illinois, Stati Uniti, 60527
- Attivo, non reclutante
- Loyola Center for Health at Burr Ridge
-
Canton, Illinois, Stati Uniti, 61520
- Attivo, non reclutante
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Stati Uniti, 62902
- Sospeso
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Stati Uniti, 62918
- Reclutamento
- SIH Cancer Institute
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 618-985-3333
- Email: clinical.research@sih.net
-
Carthage, Illinois, Stati Uniti, 62321
- Attivo, non reclutante
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Stati Uniti, 62801
- Sospeso
- Centralia Oncology Clinic
-
Chicago, Illinois, Stati Uniti, 60657
- Reclutamento
- Advocate Illinois Masonic Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-296-5360
-
Investigatore principale:
- Thomas J. Saphner
-
Crystal Lake, Illinois, Stati Uniti, 60014
- Reclutamento
- AMG Crystal Lake - Oncology
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-929-6129
- Email: advocateresearch@advocate.com
-
Investigatore principale:
- Thomas J. Saphner
-
Danville, Illinois, Stati Uniti, 61832
- Reclutamento
- Carle at The Riverfront
-
Investigatore principale:
- Prem Sobti
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@Carle.com
-
Decatur, Illinois, Stati Uniti, 62526
- Reclutamento
- Cancer Care Specialists of Illinois - Decatur
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Stati Uniti, 62526
- Sospeso
- Decatur Memorial Hospital
-
Dixon, Illinois, Stati Uniti, 61021
- Attivo, non reclutante
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Stati Uniti, 60515
- Reclutamento
- Advocate Good Samaritan Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-275-1270
- Email: Barbara.barhamand@advocatehealth.com
-
Investigatore principale:
- Thomas J. Saphner
-
Effingham, Illinois, Stati Uniti, 62401
- Reclutamento
- Carle Physician Group-Effingham
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Investigatore principale:
- Prem Sobti
-
Effingham, Illinois, Stati Uniti, 62401
- Reclutamento
- Crossroads Cancer Center
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Stati Uniti, 60123
- Reclutamento
- Advocate Sherman Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-429-2907
-
Investigatore principale:
- Thomas J. Saphner
-
Eureka, Illinois, Stati Uniti, 61530
- Attivo, non reclutante
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Stati Uniti, 61401
- Sospeso
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Stati Uniti, 61401
- Attivo, non reclutante
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Stati Uniti, 60429
- Reclutamento
- Advocate South Suburban Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 708-799-9995
-
Investigatore principale:
- Thomas J. Saphner
-
Homer Glen, Illinois, Stati Uniti, 60491
- Attivo, non reclutante
- Loyola Medicine Homer Glen
-
Kewanee, Illinois, Stati Uniti, 61443
- Attivo, non reclutante
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Stati Uniti, 60048
- Reclutamento
- AMG Libertyville - Oncology
-
Contatto:
- Site Public Contact
- Numero di telefono: 630-929-6129
- Email: advocateresearch@advocatehealth.com
-
Investigatore principale:
- Thomas J. Saphner
-
Macomb, Illinois, Stati Uniti, 61455
- Attivo, non reclutante
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Stati Uniti, 61938
- Reclutamento
- Carle Physician Group-Mattoon/Charleston
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Investigatore principale:
- Prem Sobti
-
Maywood, Illinois, Stati Uniti, 60153
- Attivo, non reclutante
- Loyola University Medical Center
-
Melrose Park, Illinois, Stati Uniti, 60160
- Attivo, non reclutante
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Stati Uniti, 62864
- Reclutamento
- SSM Health Good Samaritan
-
Investigatore principale:
- Jay W. Carlson
-
Contatto:
- Site Public Contact
- Numero di telefono: 618-899-1894
- Email: gayla.hall@ssmhealth.com
-
O'Fallon, Illinois, Stati Uniti, 62269
- Reclutamento
- Cancer Care Center of O'Fallon
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Stati Uniti, 60453-2699
- Reclutamento
- Advocate Christ Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-323-8622
-
Investigatore principale:
- Thomas J. Saphner
-
Ottawa, Illinois, Stati Uniti, 61350
- Attivo, non reclutante
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Stati Uniti, 60068
- Reclutamento
- Advocate Lutheran General Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-384-3621
-
Investigatore principale:
- Thomas J. Saphner
-
Pekin, Illinois, Stati Uniti, 61554
- Attivo, non reclutante
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stati Uniti, 61636
- Sospeso
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Stati Uniti, 61615
- Attivo, non reclutante
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stati Uniti, 61354
- Sospeso
- Valley Radiation Oncology
-
Peru, Illinois, Stati Uniti, 61354
- Attivo, non reclutante
- Illinois CancerCare-Peru
-
Princeton, Illinois, Stati Uniti, 61356
- Attivo, non reclutante
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Southern Illinois University School of Medicine
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-545-7929
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Springfield Clinic
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-444-7541
-
Springfield, Illinois, Stati Uniti, 62781
- Sospeso
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Reclutamento
- Carle Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Investigatore principale:
- Prem Sobti
-
Washington, Illinois, Stati Uniti, 61571
- Attivo, non reclutante
- Illinois CancerCare - Washington
-
-
Indiana
-
Richmond, Indiana, Stati Uniti, 47374
- Attivo, non reclutante
- Reid Health
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Attivo, non reclutante
- Mary Greeley Medical Center
-
Ames, Iowa, Stati Uniti, 50010
- Attivo, non reclutante
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Stati Uniti, 52722
- Reclutamento
- University of Iowa Healthcare Cancer Services Quad Cities
-
Investigatore principale:
- Fernando Maciel Barbosa
-
Contatto:
- Site Public Contact
- Numero di telefono: 563-355-7733
- Email: katherine-daprile@uiowa.edu
-
Boone, Iowa, Stati Uniti, 50036
- Attivo, non reclutante
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Stati Uniti, 50501
- Attivo, non reclutante
- McFarland Clinic - Trinity Cancer Center
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Investigatore principale:
- Fernando Maciel Barbosa
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-237-1225
-
Jefferson, Iowa, Stati Uniti, 50129
- Attivo, non reclutante
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Stati Uniti, 50158
- Attivo, non reclutante
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Stati Uniti, 67846
- Sospeso
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Stati Uniti, 67530
- Sospeso
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Reclutamento
- University of Kentucky/Markey Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 859-257-3379
-
Investigatore principale:
- Patrick J. Hensley
-
-
Louisiana
-
Baton Rouge, Louisiana, Stati Uniti, 70809
- Reclutamento
- Mary Bird Perkins Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 225-215-1353
- Email: clinicalresearch@marybird.com
-
Investigatore principale:
- Victor T. Lin
-
Metairie, Louisiana, Stati Uniti, 70006
- Reclutamento
- East Jefferson General Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-210-3539
- Email: emede1@lsuhsc.edu
-
Investigatore principale:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Stati Uniti, 70006
- Reclutamento
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-210-3539
- Email: emede1@lsuhsc.edu
-
Investigatore principale:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Stati Uniti, 70002
- Reclutamento
- Mary Bird Perkins Cancer Center - Metairie
-
Investigatore principale:
- Victor T. Lin
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-584-6990
-
New Orleans, Louisiana, Stati Uniti, 70112
- Reclutamento
- University Medical Center New Orleans
-
Contatto:
- Site Public Contact
- Numero di telefono: 504-210-3539
- Email: emede1@lsuhsc.edu
-
Investigatore principale:
- Rajasree P. Chowdry
-
-
Maine
-
Augusta, Maine, Stati Uniti, 04330
- Reclutamento
- Harold Alfond Center for Cancer Care
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-626-4855
-
Investigatore principale:
- Erin Adler
-
Biddeford, Maine, Stati Uniti, 04005
- Sospeso
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Stati Uniti, 04073
- Reclutamento
- MaineHealth Cancer Care Center of York County
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-459-1600
-
Investigatore principale:
- Erin Adler
-
Sanford, Maine, Stati Uniti, 04073
- Reclutamento
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
Investigatore principale:
- Erin Adler
-
Scarborough, Maine, Stati Uniti, 04074
- Reclutamento
- MaineHealth Maine Medical Center- Scarborough
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
Investigatore principale:
- Erin Adler
-
South Portland, Maine, Stati Uniti, 04106
- Reclutamento
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Contatto:
- Site Public Contact
- Numero di telefono: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
Investigatore principale:
- Erin Adler
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 410-955-8804
- Email: jhcccro@jhmi.edu
-
Investigatore principale:
- Jean H. Hoffman-Censits
-
-
Massachusetts
-
Worcester, Massachusetts, Stati Uniti, 01655
- Reclutamento
- UMass Memorial Medical Center - University Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 508-856-3216
- Email: cancer.research@umassmed.edu
-
Investigatore principale:
- Kriti Mittal
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Reclutamento
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Brighton, Michigan, Stati Uniti, 48114
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Brighton, Michigan, Stati Uniti, 48114
- Reclutamento
- Trinity Health Medical Center - Brighton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Canton, Michigan, Stati Uniti, 48188
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Canton, Michigan, Stati Uniti, 48188
- Reclutamento
- Trinity Health Medical Center - Canton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Chelsea, Michigan, Stati Uniti, 48118
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Chelsea, Michigan, Stati Uniti, 48118
- Reclutamento
- Chelsea Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Clarkston, Michigan, Stati Uniti, 48346
- Reclutamento
- Hematology Oncology Consultants-Clarkston
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Clarkston, Michigan, Stati Uniti, 48346
- Sospeso
- Newland Medical Associates-Clarkston
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Genesys Hurley Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Investigatore principale:
- Elie G. Dib
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Hurley Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Investigatore principale:
- Elie G. Dib
-
Flint, Michigan, Stati Uniti, 48503
- Sospeso
- Genesee Hematology Oncology PC
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Cancer Hematology Centers - Flint
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Investigatore principale:
- Elie G. Dib
-
Livonia, Michigan, Stati Uniti, 48154
- Sospeso
- Hope Cancer Clinic
-
Livonia, Michigan, Stati Uniti, 48154
- Reclutamento
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Macomb, Michigan, Stati Uniti, 48044
- Reclutamento
- Henry Ford Saint John Hospital - Macomb Medical
-
Investigatore principale:
- Elie G. Dib
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-343-3166
- Email: kforman1@hfhs.org
-
Pontiac, Michigan, Stati Uniti, 48341
- Reclutamento
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Pontiac, Michigan, Stati Uniti, 48341
- Reclutamento
- Michigan Healthcare Professionals Pontiac
-
Investigatore principale:
- Elie G. Dib
-
Contatto:
- Site Public Contact
- Numero di telefono: 248-858-6215
- Email: Emily.Crofts@trinity-health.org
-
Pontiac, Michigan, Stati Uniti, 48341
- Reclutamento
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Saginaw, Michigan, Stati Uniti, 48604
- Sospeso
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stati Uniti, 48601
- Reclutamento
- MyMichigan Medical Center Saginaw
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Tawas City, Michigan, Stati Uniti, 48764
- Reclutamento
- MyMichigan Medical Center Tawas
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
West Branch, Michigan, Stati Uniti, 48661
- Sospeso
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Stati Uniti, 48106
- Reclutamento
- Huron Gastroenterology PC
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Elie G. Dib
-
-
Minnesota
-
Burnsville, Minnesota, Stati Uniti, 55337
- Sospeso
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Stati Uniti, 55337
- Sospeso
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Stati Uniti, 55008
- Sospeso
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Reclutamento
- Mercy Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Edina, Minnesota, Stati Uniti, 55435
- Sospeso
- Fairview Southdale Hospital
-
Edina, Minnesota, Stati Uniti, 55435
- Reclutamento
- Minnesota Oncology - Edina
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Fridley, Minnesota, Stati Uniti, 55432
- Attivo, non reclutante
- Unity Hospital
-
Maple Grove, Minnesota, Stati Uniti, 55369
- Sospeso
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Stati Uniti, 55109
- Reclutamento
- Minnesota Oncology Hematology PA-Maplewood
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Maplewood, Minnesota, Stati Uniti, 55109
- Sospeso
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Sospeso
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Sospeso
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Stati Uniti, 55454
- Sospeso
- Health Partners Inc
-
Monticello, Minnesota, Stati Uniti, 55362
- Sospeso
- Monticello Cancer Center
-
New Ulm, Minnesota, Stati Uniti, 56073
- Sospeso
- New Ulm Medical Center
-
Princeton, Minnesota, Stati Uniti, 55371
- Sospeso
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Stati Uniti, 55422
- Sospeso
- North Memorial Medical Health Center
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic in Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 855-776-0015
-
Investigatore principale:
- Lance C. Pagliaro
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Reclutamento
- Park Nicollet Clinic - Saint Louis Park
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Reclutamento
- Regions Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Saint Paul, Minnesota, Stati Uniti, 55102
- Sospeso
- United Hospital
-
Shakopee, Minnesota, Stati Uniti, 55379
- Sospeso
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Stati Uniti, 55082
- Reclutamento
- Lakeview Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Waconia, Minnesota, Stati Uniti, 55387
- Sospeso
- Ridgeview Medical Center
-
Willmar, Minnesota, Stati Uniti, 56201
- Sospeso
- Rice Memorial Hospital
-
Woodbury, Minnesota, Stati Uniti, 55125
- Reclutamento
- Minnesota Oncology Hematology PA-Woodbury
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- David M. King
-
Wyoming, Minnesota, Stati Uniti, 55092
- Sospeso
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Stati Uniti, 63011
- Sospeso
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Stati Uniti, 65613
- Sospeso
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Reclutamento
- Saint Francis Medical Center
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 573-334-2230
- Email: sfmc@sfmc.net
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Sospeso
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Stati Uniti, 63640
- Reclutamento
- Parkland Health Center - Farmington
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
Jefferson City, Missouri, Stati Uniti, 65109
- Sospeso
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Stati Uniti, 64804
- Sospeso
- Freeman Health System
-
Joplin, Missouri, Stati Uniti, 64804
- Sospeso
- Mercy Hospital Joplin
-
Rolla, Missouri, Stati Uniti, 65401
- Sospeso
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Stati Uniti, 65401
- Sospeso
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Stati Uniti, 64506
- Sospeso
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Stati Uniti, 63670
- Reclutamento
- Sainte Genevieve County Memorial Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
Springfield, Missouri, Stati Uniti, 65804
- Sospeso
- Mercy Hospital Springfield
-
Springfield, Missouri, Stati Uniti, 65807
- Sospeso
- CoxHealth South Hospital
-
St Louis, Missouri, Stati Uniti, 63128
- Reclutamento
- Mercy Hospital South
-
Investigatore principale:
- Jay W. Carlson
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-525-6042
- Email: Danielle.Werle@mercy.net
-
St Louis, Missouri, Stati Uniti, 63141
- Reclutamento
- Mercy Hospital Saint Louis
-
Investigatore principale:
- Jay W. Carlson
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-251-7066
-
St Louis, Missouri, Stati Uniti, 63109
- Sospeso
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Stati Uniti, 63131
- Reclutamento
- Missouri Baptist Medical Center
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
Sullivan, Missouri, Stati Uniti, 63080
- Reclutamento
- Missouri Baptist Sullivan Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-996-5569
-
Washington, Missouri, Stati Uniti, 63090
- Sospeso
- Mercy Hospital Washington
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89102
- Sospeso
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Stati Uniti, 89183
- Sospeso
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- Completato
- Hackensack University Medical Center
-
Livingston, New Jersey, Stati Uniti, 07039
- Reclutamento
- Cooperman Barnabas Medical Center
-
Investigatore principale:
- Saum B. Ghodoussipour
-
Contatto:
- Site Public Contact
- Numero di telefono: 973-322-5200
-
New Brunswick, New Jersey, Stati Uniti, 08903
- Reclutamento
- Rutgers Cancer Institute of New Jersey
-
Investigatore principale:
- Saum B. Ghodoussipour
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-235-7356
-
Toms River, New Jersey, Stati Uniti, 08755
- Reclutamento
- Community Medical Center
-
Investigatore principale:
- Saum B. Ghodoussipour
-
Contatto:
- Site Public Contact
- Numero di telefono: 732-557-8294
- Email: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- Reclutamento
- University of New Mexico Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 505-925-0348
- Email: HSC-ClinicalTrialInfo@salud.unm.edu
-
Investigatore principale:
- Amy C. Tarnower
-
-
New York
-
Buffalo, New York, Stati Uniti, 14263
- Attivo, non reclutante
- Roswell Park Cancer Institute
-
-
North Carolina
-
Clinton, North Carolina, Stati Uniti, 28328
- Reclutamento
- Southeastern Medical Oncology Center-Clinton
-
Contatto:
- Site Public Contact
- Numero di telefono: 919-587-9084
- Email: jfields@cancersmoc.com
-
Investigatore principale:
- Samer S. Kasbari
-
Goldsboro, North Carolina, Stati Uniti, 27534
- Reclutamento
- Southeastern Medical Oncology Center-Goldsboro
-
Contatto:
- Site Public Contact
- Numero di telefono: 919-587-9084
- Email: jfields@cancersmoc.com
-
Investigatore principale:
- Samer S. Kasbari
-
Jacksonville, North Carolina, Stati Uniti, 28546
- Reclutamento
- Southeastern Medical Oncology Center-Jacksonville
-
Investigatore principale:
- Samer S. Kasbari
-
Contatto:
- Site Public Contact
- Numero di telefono: 910-587-9084
- Email: jfields@cancersmoc.com
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Attivo, non reclutante
- Wake Forest University Health Sciences
-
-
Ohio
-
Centerville, Ohio, Stati Uniti, 45459
- Reclutamento
- Miami Valley Hospital South
-
Contatto:
- Site Public Contact
- Numero di telefono: 937-528-2900
- Email: clinical.trials@daytonncorp.org
-
Investigatore principale:
- Tarek M. Sabagh
-
Centerville, Ohio, Stati Uniti, 45459
- Attivo, non reclutante
- Dayton Physicians LLC-Miami Valley South
-
Dayton, Ohio, Stati Uniti, 45409
- Reclutamento
- Miami Valley Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 937-528-2900
- Email: clinical.trials@daytonncorp.org
-
Investigatore principale:
- Tarek M. Sabagh
-
Dayton, Ohio, Stati Uniti, 45415
- Reclutamento
- Miami Valley Hospital North
-
Contatto:
- Site Public Contact
- Numero di telefono: 937-528-2900
- Email: clinical.trials@daytonncorp.org
-
Investigatore principale:
- Tarek M. Sabagh
-
Dayton, Ohio, Stati Uniti, 45409
- Reclutamento
- Premier Blood and Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 937-276-8320
-
Investigatore principale:
- Tarek M. Sabagh
-
Dayton, Ohio, Stati Uniti, 45415
- Attivo, non reclutante
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Stati Uniti, 45840
- Attivo, non reclutante
- Armes Family Cancer Center
-
Franklin, Ohio, Stati Uniti, 45005-1066
- Reclutamento
- Atrium Medical Center-Middletown Regional Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 937-528-2900
- Email: clinical.trials@daytonncorp.org
-
Investigatore principale:
- Tarek M. Sabagh
-
Franklin, Ohio, Stati Uniti, 45005
- Attivo, non reclutante
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Stati Uniti, 45331
- Reclutamento
- Miami Valley Cancer Care and Infusion
-
Investigatore principale:
- Tarek M. Sabagh
-
Contatto:
- Site Public Contact
- Numero di telefono: 937-569-7515
-
Kettering, Ohio, Stati Uniti, 45409
- Attivo, non reclutante
- Greater Dayton Cancer Center
-
Kettering, Ohio, Stati Uniti, 45429
- Attivo, non reclutante
- Kettering Medical Center
-
Springfield, Ohio, Stati Uniti, 45504
- Sospeso
- Springfield Regional Cancer Center
-
Sylvania, Ohio, Stati Uniti, 43560
- Reclutamento
- ProMedica Flower Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 419-824-1842
- Email: PCIOncResearch@promedica.org
-
Investigatore principale:
- Jeffrey H. Muler
-
Troy, Ohio, Stati Uniti, 45373
- Reclutamento
- Upper Valley Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 937-528-2900
- Email: clinical.trials@daytonncorp.org
-
Investigatore principale:
- Tarek M. Sabagh
-
-
Oklahoma
-
Lawton, Oklahoma, Stati Uniti, 73505
- Reclutamento
- Cancer Centers of Southwest Oklahoma Research
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-231-4440
-
Investigatore principale:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Stati Uniti, 73120
- Sospeso
- Mercy Hospital Oklahoma City
-
-
Pennsylvania
-
Erie, Pennsylvania, Stati Uniti, 16505
- Reclutamento
- UPMC Hillman Cancer Center Erie
-
Investigatore principale:
- Leonard J. Appleman
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-864-7716
- Email: ClinicalResearchServices@upmc.edu
-
Greensburg, Pennsylvania, Stati Uniti, 15601
- Reclutamento
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Contatto:
- Site Public Contact
- Numero di telefono: 724-838-1900
-
Investigatore principale:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Stati Uniti, 17033-0850
- Reclutamento
- Penn State Milton S Hershey Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 717-531-3779
- Email: CTO@hmc.psu.edu
-
Investigatore principale:
- Monika Joshi
-
Monroeville, Pennsylvania, Stati Uniti, 15146
- Reclutamento
- UPMC Hillman Cancer Center - Monroeville
-
Investigatore principale:
- Leonard J. Appleman
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-864-7716
- Email: ClinicalResearchServices@upmc.edu
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Reclutamento
- Thomas Jefferson University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 215-600-9151
- Email: ONCTrialNow@jefferson.edu
-
Investigatore principale:
- William J. Tester
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- University of Pennsylvania/Abramson Cancer Center
-
Investigatore principale:
- Ronac Mamtani
-
Contatto:
- Site Public Contact
- Numero di telefono: 215-349-8245
- Email: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Stati Uniti, 15237
- Reclutamento
- UPMC-Passavant Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-367-6454
-
Investigatore principale:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Stati Uniti, 15243
- Reclutamento
- UPMC-Saint Clair Hospital Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-502-3920
-
Investigatore principale:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- UPMC Hillman Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-647-8073
-
Investigatore principale:
- Leonard J. Appleman
-
Washington, Pennsylvania, Stati Uniti, 15301
- Reclutamento
- UPMC Cancer Center-Washington
-
Contatto:
- Site Public Contact
- Email: ecog.rss@jimmy.harvard.edu
-
Investigatore principale:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Stati Uniti, 19611
- Reclutamento
- Reading Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 610-988-9323
-
Investigatore principale:
- Terrence P. Cescon
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Attivo, non reclutante
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contatto:
- Site Public Contact
- Numero di telefono: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Investigatore principale:
- Vitaly Margulis
-
Dallas, Texas, Stati Uniti, 75235
- Reclutamento
- Parkland Memorial Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 214-590-5582
- Email: canceranswerline@UTSouthwestern.edu
-
Investigatore principale:
- Vitaly Margulis
-
Dallas, Texas, Stati Uniti, 75237
- Sospeso
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contatto:
- Site Public Contact
- Numero di telefono: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Investigatore principale:
- Vitaly Margulis
-
Richardson, Texas, Stati Uniti, 75080
- Reclutamento
- UT Southwestern Clinical Center at Richardson/Plano
-
Contatto:
- Site Public Contact
- Numero di telefono: 972-669-7044
- Email: Suzanne.cole@utsouthwestern.edu
-
Investigatore principale:
- Vitaly Margulis
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- Reclutamento
- University of Washington Medical Center - Montlake
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-8824
-
Investigatore principale:
- Petros Grivas
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Fred Hutchinson Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-804-8824
-
Investigatore principale:
- Petros Grivas
-
-
West Virginia
-
Charleston, West Virginia, Stati Uniti, 25304
- Reclutamento
- Vandalia Health/CAMC Institute for Academic Medicine
-
Investigatore principale:
- Kok Hoe Chan
-
Contatto:
- Site Public Contact
- Numero di telefono: 304-388-9944
- Email: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Stati Uniti, 54911
- Reclutamento
- ThedaCare Regional Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-364-3604
- Email: ResearchDept@thedacare.org
-
Investigatore principale:
- Matthias Weiss
-
Burlington, Wisconsin, Stati Uniti, 53105
- Reclutamento
- Aurora Cancer Care-Southern Lakes VLCC
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Reclutamento
- Marshfield Medical Center-EC Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Germantown, Wisconsin, Stati Uniti, 53022
- Reclutamento
- Aurora Health Care Germantown Health Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Grafton, Wisconsin, Stati Uniti, 53024
- Reclutamento
- Aurora Cancer Care-Grafton
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Stati Uniti, 54311
- Reclutamento
- Aurora BayCare Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Kenosha, Wisconsin, Stati Uniti, 53142
- Reclutamento
- Aurora Cancer Care-Kenosha South
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Marinette, Wisconsin, Stati Uniti, 54143
- Reclutamento
- Aurora Bay Area Medical Group-Marinette
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Reclutamento
- Marshfield Medical Center-Marshfield
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Milwaukee, Wisconsin, Stati Uniti, 53209
- Reclutamento
- Aurora Cancer Care-Milwaukee
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Reclutamento
- Aurora Saint Luke's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Stati Uniti, 53233
- Reclutamento
- Aurora Sinai Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Reclutamento
- Marshfield Medical Center - Minocqua
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Mukwonago, Wisconsin, Stati Uniti, 53149
- Reclutamento
- ProHealth D N Greenwald Center
-
Contatto:
- Site Public Contact
- Email: research.institute@phci.org
-
Investigatore principale:
- Timothy R. Wassenaar
-
New Richmond, Wisconsin, Stati Uniti, 54017
- Sospeso
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- Reclutamento
- ProHealth Oconomowoc Memorial Hospital
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-7878
-
Oshkosh, Wisconsin, Stati Uniti, 54904
- Reclutamento
- Vince Lombardi Cancer Clinic - Oshkosh
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Racine, Wisconsin, Stati Uniti, 53406
- Reclutamento
- Aurora Cancer Care-Racine
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Reclutamento
- Marshfield Medical Center-Rice Lake
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Sheboygan, Wisconsin, Stati Uniti, 53081
- Reclutamento
- Vince Lombardi Cancer Clinic-Sheboygan
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Reclutamento
- Marshfield Medical Center-River Region at Stevens Point
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Summit, Wisconsin, Stati Uniti, 53066
- Reclutamento
- Aurora Medical Center in Summit
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Stati Uniti, 54241
- Reclutamento
- Vince Lombardi Cancer Clinic-Two Rivers
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Reclutamento
- ProHealth Waukesha Memorial Hospital
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-7632
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Reclutamento
- UW Cancer Center at ProHealth Care
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-5539
- Email: Chanda.miller@phci.org
-
Waupaca, Wisconsin, Stati Uniti, 54981
- Reclutamento
- ThedaCare Cancer Care - Waupaca
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-364-3605
- Email: ResearchDept@thedacare.org
-
Investigatore principale:
- Matthias Weiss
-
Wauwatosa, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Aurora Cancer Care-Milwaukee West
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
West Allis, Wisconsin, Stati Uniti, 53227
- Reclutamento
- Aurora West Allis Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-302-2304
- Email: ncorp@aurora.org
-
Investigatore principale:
- Thomas J. Saphner
-
Weston, Wisconsin, Stati Uniti, 54476
- Reclutamento
- Marshfield Medical Center - Weston
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
STEP 1 REGISTRATION AND RANDOMIZATION
-
Patients must be >= 18 years of age
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Patient must have a diagnosis of high grade upper tract urothelial carcinoma expected within 14 weeks (98 days) prior to registration/randomization with one of the following:
-
Biopsy (gold standard, preferred) and either upper urinary tract mass on cross-sectional imaging or tumor directly visualized during upper urinary tract endoscopy
-
High grade cytology and clinically estimated invasive upper urinary tract mass on cross-sectional imaging (e.g., including presence of tumor-related hydronephrosis) or tumor directly visualized during upper urinary tract endoscopy
-
NOTE: Universal histologic testing of UTUC with additional studies, such as immunohistochemistry and/or microsatellite instability, is strongly recommended to identify patients with high probability of Lynch-related or other germline mutation related cancers whom clinicians should refer for genetic counseling and germline testing (this is not required for eligibility)
- Due to the anatomy of upper urinary tract and lack of muscularis propria, pathologic evidence of cT2 on biopsy is usually not possible
-
-
-
Patients must not have any component of small cell/neuroendocrine carcinoma. Other histologic subtypes (variants) are permitted provided the half or predominant (>= 50%) subtype is conventional urothelial carcinoma
-
Leukocytes >= 3,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Platelets >= 100,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Total bilirubin =< 1.2 mg/dL (or ≤ 2 mg/dL for patients with Gilbert's disease)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN (obtained =< 14 days prior to registration/randomization)
-
Hemoglobin (Hgb) >= 9 g/dL (obtained =< 14 days prior to registration/randomization)
- NOTE: Packed red blood transfusion is allowed to achieve this parameter as per treating investigator
-
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients of childbearing potential and sexually active patients must not expect to conceive or father children, either by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment and for at least 6 months after the last dose of protocol treatment
-
Patients must have no evidence of metastatic disease or clinically enlarged regional lymph nodes (>= 1.5 cm short axis) on imaging required within 28 days prior to registration (Non-regional findings >=1.5 cm short axis that in the opinion of the investigator are not concerning for involvement based on radiographic characteristics, chronicity, avidity on positron emission tomography (PET) scan or other imaging or other criteria can be eligible based on investigator discretion).
- NOTE: Patients with elevated alkaline phosphatase, calcium or suspicious bone pain/tenderness can also undergo baseline bone scan to evaluate for bone metastasis at the discretion of local provider.
-
Patient must meet below criteria for prior/current malignancy history:
-
Non-urothelial cancer malignancy history:
-
Patient must not have another active (or within two years) second malignancy other than resected non-melanoma skin cancers, resected in situ breast, cervical or other in situ carcinoma, and either clinically insignificant per the investigator (e.g. =< Gleason 3+4) on active surveillance (or watchful waiting) or previously treated prostate cancer with no rising prostate specific antigen (PSA) and no plan to treat
- NOTE: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Urothelial cancer malignancy history:
- Patient may have a history of resectable urothelial cancer as long as patients meet one of the following:
- T0, Ta or Tis at any time
- T1-4a N0 and no evidence of disease (NED) for more than 2 years from the latest therapy [e.g., radical surgery, transurethral resection of bladder tumor (TURBT), radiation, chemotherapy (neoadjuvant or adjuvant, or with radiation)]. Prior systemic immune checkpoint inhibitor is not allowed.
- Patient with history of >= pT4b, N+, and/or M1 UC is not eligible.
- NOTE: Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only Ta or carcinoma in situ (CIS) (< cT1 N0) are eligible regardless of time elapsed
-
-
-
Patient must not have any uncontrolled illness including, but not limited to, ongoing or active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), symptomatic congestive heart failure (CHF), myocardial infarction (MI) or unstable angina pectoris, significant uncontrolled cardiac arrhythmia, clinically relevant liver cirrhosis, interstitial lung disease, or psychiatric illness/social situations in the three months prior to registration that would limit compliance with study requirements
-
Patient must not have received prior radiation therapy to >= 25% of the bone marrow for other diseases
-
Patient must not have received prior systemic anthracycline therapy
- NOTE: Patients who have received prior intravesical therapy at any time for non-muscle invasive urothelial carcinoma of the bladder are eligible
-
Patient must not have either history of or active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration/randomization or any history of inflammatory bowel disease (inflammatory bowel disease [IBD], e.g. ulcerative colitis, or Crohn's disease), neuromuscular autoimmune condition, immune-related pneumonitis or interstitial lung disease. Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diabetes mellitus type I, vitiligo, alopecia, psoriasis, eczema, lichen planus, or similar skin/mucosa condition are eligible
-
Patient must not be on or have used immunosuppressive medication within 14 days prior to the first dose of durvalumab. The following are exceptions to this criterion and are allowed:
- Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g. intra-articular injection
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent at the time of enrollment
- Steroids as pre-medications for hypersensitivity reactions (e.g. computed tomography [CT] pre-medication)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration/randomization are eligible for this trial
- NOTE: These patients must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks. They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy induced bone marrow suppression. They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
- NOTE: For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy. They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of registration/randomization
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- NOTE: Testing for HIV, hepatitis B or hepatitis C is not required unless clinically indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and have undetectable viral load. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab, while on protocol treatment and within 30 days after the last dose of durvalumab
-
Patient must not have had a major surgical procedure within 28 days prior to registration/randomization
- NOTE: Cystoscopy/ureteroscopy/TURBT, stent placement or nephrostomy tube is not considered major surgery
-
Patient must not have history of allogenic organ transplantation
-
Patient must have a body weight of > 30 kg
-
Patient must have life expectancy of >= 12 weeks
-
Patient must have creatinine clearance > 15 ml/min as estimated by Cockcroft-Gault formula or glomerular filtration rate (GFR) > 15 ml/min/1.73m^2 within 28 days prior to registration/randomization
-
NOTE: Patients will be assigned to cisplatin-ineligible and cisplatin-eligible cohorts based on their creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, and grade (if any) of peripheral neuropathy and/or hearing loss in keeping with recommended cisplatin contraindications. Patients who are cisplatin-eligible will be randomized to either Arm A or Arm B and patients who are cisplatin-ineligible will be registered to Arm C
-
Patients that meet any of the following four criteria will be registered to the cisplatin-ineligible Arm C if they meet other eligibility criteria:
- Creatinine clearance > 15 ml/min and =< 50 ml/min (estimated by Cockcroft-Gault formula) or GFR > 15ml/min/1.73m^2 and ≤ 50 ml/min/1.73 m^2
- Hearing loss >= 3
- Neuropathy >= 2
- ECOG performance status 2
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,000/mcL obtained =< 14 days prior to registration
-
Patients that meet all of the following four criteria will be randomized to the cisplatin-eligible Arm A or Arm B:
- Creatinine clearance > 50ml/min (estimated by Cockcroft-Gault formula) or GFR > 50ml/min/1.73m^2
- ECOG performance status 0-1
- Hearing loss grade 0-2
- Neuropathy 0-1
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,500/mcL obtained =< 14 days prior to randomization
-
Also, the patient must have left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition scan [MUGA] or 2-D echocardiogram) obtained within obtained within 28 days prior to randomization
-
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm A (durvalumab, chemotherapy)
Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo surgery Undergo tissue biopsy
Altri nomi:
Given IV
Altri nomi:
Given Iv
Altri nomi:
Given via injection
Altri nomi:
Given Iv
Altri nomi:
|
|
Comparatore attivo: Arm B (chemotherapy)
Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Altri nomi:
Undergo blood sample collection
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo surgery Undergo tissue biopsy
Altri nomi:
Given Iv
Altri nomi:
Given via injection
Altri nomi:
Given Iv
Altri nomi:
|
|
Sperimentale: Arm C (durvalumab, gemcitabine hydrochloride)
Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Given IV
Altri nomi:
Undergo surgery Undergo tissue biopsy
Altri nomi:
Given IV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)
Lasso di tempo: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Disease progression prior to surgery or omission of surgery due to unresectable tumors, muscle-invasive cancer or disease recurring outside of the bladder, urethra, or contralateral upper tract are considered as events for EFS. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)
Lasso di tempo: At surgery
|
Will assess pathologic complete response at surgery (pCR, pT0N0/Nx) by local pathology review. Patients who drop out prior to surgery or who have unknown response status will be considered as non-responders. |
At surgery
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
pCR (coorte idonea al cisplatino: braccia A e B)
Lasso di tempo: Fino a 5 anni
|
Fino a 5 anni
|
|
|
EFS (cisplatin-ineligible cohort: Arm C)
Lasso di tempo: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Will be characterized using the Kaplan-Meier method. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Overall survival (OS) (All Patients)
Lasso di tempo: From registration/randomization to death from any cause, assessed up to 5 years
|
OS will be evaluated by arm, post chemotherapy response (ypCR, stage yp =< T1N0, yp >= T2N0), as well as stage (ypCR and > ypCR) within and across treatment arms. Will be estimated using Kaplan-Meier method. |
From registration/randomization to death from any cause, assessed up to 5 years
|
|
Urothelial cancer-free survival or disease-free survival (All Patients)
Lasso di tempo: From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
A return of UTUC includes non-muscle invasive recurrences, pathologic T2 or higher muscle-invasive recurrences specifically in the urinary tract, metastatic disease outside the urinary tract, or death. Patients alive without documented UTUC will be censored at the date of last disease assessment. |
From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
|
Cancer-specific survival (All Patients)
Lasso di tempo: From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
Will be analyzed using Gray's method and cumulative incidence estimates will be reported. |
From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
|
Renal function outcomes following systemic treatment and following radical nephroureterectomy (All Patients)
Lasso di tempo: Post chemotherapy and post surgery
|
The proportion of patients with renal insufficiency (creatinine [CrCl] < 60 ml/min) post chemotherapy and post nephroureterectomy as well as the proportion of patients with renal function improvement (CrCl < 60 ml/min at baseline and CrCl >= 60 ml/min on study) will be reported along with exact binomial confidence intervals. The distribution of changes in renal function post chemotherapy as well as post surgery from baseline will also be reported. The analysis of renal function outcomes will be performed among patients who receive at least one dose of study therapy. |
Post chemotherapy and post surgery
|
|
Incidence of adverse events (All Patients)
Lasso di tempo: Up to 30 days post surgery
|
Toxicity will be evaluated in all treated patients. |
Up to 30 days post surgery
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Jean H Hoffman-Censits, ECOG-ACRIN Cancer Research Group
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Aminoacidi, peptidi e proteine
- Proteine
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Tecniche citologiche
- Citodiagnosi
- Idrocarburi
- Idrocarburi, ciclici
- Carboidrati
- Alcaloidi
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glicosidi
- Indoli
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Elementi
- Metalli
- Tecniche diagnostiche, chirurgiche
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Pterins
- Pteridine
- Metalli, pesante
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Aminopterino
- Antracicline
- Naftaceni
- Aminoglicosidi
- Isotipi di immunoglobulina
- Solfuri
- Anioni
- Ioni
- Elettroliti
- Idrogeno solforato
- Composti di platino
- Daunorubicina
- Elementi di transizione
- Gemcitabina
- Metotrexato
- Doxorubicina
- Immunoglobulina G
- Cisplatino
- Vinblastina
- 1,2-diamminocicloesaneplatino II citrato
- Biopsia
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Durvalumab
- Disolfuri
- Platino
- Merphos
- pegfilgrastim
- fattore stimolante le colonie di granulociti
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2020-09850
- U10CA180820 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2020-09850 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- EA8192 (Altro identificatore: CTEP)
- EA8192 (Altro identificatore: ECOG-ACRIN Cancer Research Group)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .